Table 1 Patient characteristics by sex of patients on hospital admission with acute myocardial infarction (AMI)

9,969

3,420

13,389

Ethnicity

Chinese

6,481 (65.0%)

2,361 (69.0%)

8,842

<0.001

Malay

2,019 (20.3%)

655 (19.2%)

2,674

Indian

1,469 (14.7%)

404 (11.8%)

1,873

Age (years)

Median

58

70

61

<0.001

Range

22-101

27-100

22-101

Age-group (years)

22-59

5,446 (54.6%)

675 (19.7%)

6,121

<0.001

60-69

2,461 (24.7%)

954 (27.9%)

3,415

70-79

1,529 (15.3%)

1,151 (33.7%)

2,680

80-101

533 (5.4%)

640 (18.7%)

1,173

Medical history

Prior MI

1,031 (10.3%)

359 (10.5%)

1,390

0.73

Prior CABG

270 (2.7%)

98 (2.9%)

368

0.63

Diabetes mellitus

3,128 (31.4%)

1,759 (51.4%)

4,887

<0.001

Hypertension

5,212 (52.3%)

2,455 (71.8%)

7,667

<0.001

Hyperlipidemia

4,178 (41.9%)

1,503 (43.9%)

5,681

0.025

Renal failure

410 (4.1%)

283 (8.3%)

693

<0.001

MI category

STEMI

4,878 (48.9%)

1,288 (37.7%)

6,166

<0.001

NSTEMI

5,091

2,132

7,223

Killip class

I

7,460 (74.8%)

2,143 (62.7%)

9,603

<0.001

II

1,752 (17.6%)

847 (24.8%)

2,599

III

568 (5.7%)

350 (10.2%)

918

IV

189 (1.9%)

80 (2.3%)

269

Reperfusion therapy

Primary and Salvage PCI or Emergency CABG

4,524 (45.4%)

911 (26.6%)

5,435

<0.001

Medical therapy

Aspirin

9,096 (91.2%)

2,932 (85.7%)

12,028

<0.001

Β-Blocker

7,806 (78.3%)

2,426 (70.9%)

10,232

<0.001

Glycoprotein IIb/IIIa Inhibitors

775 (7.8%)

199 (5.8%)

974

<0.001

Thienopyridine

5,829 (58.5%)

1,671 (48.9%)

7,500

<0.001

ACE inhibitors

6,552 (65.7%)

2,249 (65.7%)

8,801

0.97

Lipid-Lowering therapy

8,009 (80.3%)

2,518 (73.6%)

10,527

<0.001